Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PCRX Pacira Pharmaceuticals

Post-Mkt 01-21 17:50:21 EST

20.24

+0.94

+4.87%

盘后20.24

+0.000.00%

16:32 EST

High20.25	Low19.28	Vol1.10M
Open19.30	D1 Closing19.30	Amplitude5.05%
Mkt Cap870.75M	Tradable Cap765.96M	Total Shares43.02M
T/O21.93M	T/O Rate2.91%	Tradable Shares37.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":20.24,"timestamp":1769029200000,"preClose":19.3,"halted":0,"volume":1102044,"hourTrading":{"tag":"盘后","latestPrice":20.24,"preClose":20.24,"latestTime":"16:32 EST","volume":13301,"amount":269212.24,"timestamp":1769031131792,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04870466321243511,"floatShares":37844000,"shares":43021275,"eps":0.471309,"marketStatus":"Post-Mkt","change":0.94,"latestTime":"01-21 17:50:21 EST","open":19.3,"high":20.25,"low":19.275,"amount":21926372.11818,"amplitude":0.050518,"askPrice":20.64,"askSize":96,"bidPrice":9.88,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.471309,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769043600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1296709200000,"exchange":"NASDAQ","adjPreClose":19.3,"preHourTrading":{"tag":"盘前","latestPrice":19.25,"preClose":19.3,"latestTime":"09:09 EST","volume":2078,"amount":40150.91859,"timestamp":1769004584135,"change":-0.05,"changeRate":-0.002591,"amplitude":0.034715},"postHourTrading":{"tag":"盘后","latestPrice":20.24,"preClose":20.24,"latestTime":"16:32 EST","volume":13301,"amount":269212.24,"timestamp":1769031131792,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.719596,"impliedVol":0.5399,"impliedVolPercentile":0.5219},"requestUrl":"/m/hq/s/PCRX","defaultTab":"news","newsList":[{"id":"2603681026","title":"Pacira Biosciences Inc - to Receive Upfront Payment and Royalties From LG Chem","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681026","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681026?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309207,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8DJFVY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2603045681","title":"Pacira Biosciences Inc - LG Chem Gains Exclusive Rights to Commercialize Exparel","url":"https://stock-news.laohu8.com/highlight/detail?id=2603045681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603045681?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309207,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8DJFVY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2603335684","title":"Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2603335684","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603335684?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309200,"startTime":"0","endTime":"0","summary":"-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–  BRISBANE, Calif., Jan.  13, 2026  (GLOBE NEWSWIR","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217716/0/en/Pacira-Announces-Agreement-with-LG-Chem-to-Make-EXPAREL-Available-in-Select-Asian-Pacific-Markets.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007","SLCT"],"gpt_icon":0},{"id":"2603540578","title":"Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist Pressure - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540578","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603540578?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:22","pubTimestamp":1768231358,"startTime":"0","endTime":"0","summary":"Pacira BioSciences recently reported preliminary unaudited 2025 revenue of US$726.4 million, modestly above the prior year’s US$701.0 million, while also completing a US$150.05 million buyback totaling 5,932,106 shares since May 2025.\nAt the same time, the company lowered its 2025 revenue forecast and faced fresh pressure from activist DOMA Perpetual Capital Management, which is pushing for board changes and a potential sale process.\nNext, we’ll examine how the downward 2025 revenue forecast...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-63-after-cut-2025-outlook-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-63-after-cut-2025-outlook-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2602873065","title":"Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2602873065","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602873065?lang=en_us&edition=fundamental","pubTime":"2026-01-10 18:24","pubTimestamp":1768040649,"startTime":"0","endTime":"0","summary":"What triggered the latest move in Pacira BioSciences?\nPacira BioSciences (PCRX) has drawn attention after reporting record EXPAREL sales with 7% volume growth in what it called its strongest fourth quarter in three years, along with a completed fourth quarter share repurchase and fresh activist pressure on the board.\nSee our latest analysis for Pacira BioSciences.\nDespite record EXPAREL sales and a completed buyback that retired 13.28% of shares under the May 2025 program, Pacira BioSciences’...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/assessing-pacira-biosciences-pcrx-valuation-after-record-exp","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/assessing-pacira-biosciences-pcrx-valuation-after-record-exp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1103631880","title":"Stock Track | Pacira Pharmaceuticals Plummets 13.37% Intraday After Reporting Preliminary FY25 Revenue Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1103631880","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103631880?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:24","pubTimestamp":1767979457,"startTime":"0","endTime":"0","summary":"Pacira Pharmaceuticals (PCRX) saw its stock price plummet by 13.37% during intraday trading on Friday, as investors reacted to the company's preliminary FY25 revenue results.The sharp decline...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PCRX"],"gpt_icon":0},{"id":"2602087053","title":"Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January","url":"https://stock-news.laohu8.com/highlight/detail?id=2602087053","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602087053?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:21","pubTimestamp":1767979285,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/01/49818860/crude-oil-rises-sharply-us-consumer-sentiment-edges-higher-in-january","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX","USAW.SI","TQQQ","MNQmain","QID","NVIW.SI","TSYW.SI","AQST","BK4007","BK4087","PCRX",".IXIC","QLD","CGON","SQQQ","USJW.SI","QTRX","ANPA","BK4139","BK4121","PSQ","BK4082","NQmain"],"gpt_icon":1},{"id":"2602097373","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Pacira Pharmaceuticals (PCRX) and Beta Bionics, Inc. (BBNX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602097373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602097373?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961839,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME – Research Report), Pacira Pharmaceu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-pacira-pharmaceuticals-pcrx-and-beta-bionics-inc-bbnx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-pacira-pharmaceuticals-pcrx-and-beta-bionics-inc-bbnx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4137","BK4082","LABU","LU0128526141.USD","PCRX","XLV","ZYME","BK4581","BK4585","LU0029874061.USD","BBNX","XBI","HCSG","BK4588","BK4007"],"gpt_icon":0},{"id":"2602321039","title":"Pacira BioSciences Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321039","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602321039?lang=en_us&edition=fundamental","pubTime":"2026-01-09 18:01","pubTimestamp":1767952860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 05:01 ET (10:01 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2602319983","title":"Stocks to Watch: Cemtrex, Olin, Pacira BioSciences, Tilray Brands","url":"https://stock-news.laohu8.com/highlight/detail?id=2602319983","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602319983?lang=en_us&edition=fundamental","pubTime":"2026-01-09 07:32","pubTimestamp":1767915120,"startTime":"0","endTime":"0","summary":"Cemtrex completed its acquisition of a Texas military engineering firm. Shares gained 35.5% to $3.94 in after-hours trading Thursday.Olin cut its fourth-quarter outlook, citing a slowdown in operations at its Freeport, Texas, facility and a decline in chlorine demand. The stock fell 7.8% to $20.80 after the bell.Pacira BioSciences' preliminary revenue results for the year were lower than analysts were expecting. Shares declined 9.7% to $23.50.Tilray Brands said a potential rescheduling of marijuana in the U.S. could boost its medical cannabis business. Shares advanced 7.8% to $9.85.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","LU1169589451.USD","LU1169590202.USD","BK4007","BK4157","BK4596","BK4557","OLN","BK4090","BK4145","TLRY","CETX","PCRX"],"gpt_icon":0},{"id":"2602531672","title":"Pacira BioSciences Falls After Preliminary Sales Miss Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2602531672","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602531672?lang=en_us&edition=fundamental","pubTime":"2026-01-09 07:10","pubTimestamp":1767913800,"startTime":"0","endTime":"0","summary":"Shares of Pacira BioSciences slipped after the company's preliminary-revenue report came in below Wall Street estimates.The stock fell 9.7%, to $23.49, in after-hours trading Thursday. Through the close, the stock was up about 40% over the past 12 months.The Brisbane, Calif., developer of pain therapies said its preliminary unaudited revenue for 2025 is $726.4 million. That would be below the $729.5 million analysts were forecasting, according to FactSet.Preliminary sales of Exparel in the fourth quarter were $155.8 million, which would miss the $158.1 million analysts projected.Volume growth was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization partnership, Pacira said.For the full year, Exparel's preliminary sales were $575.1 million, which would miss estimates by about $2 million.Annual sales projections for Zilretta and Ioveradeg were roughly in line with Wall Street's expectations.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira BioSciences Falls After Preliminary Sales Miss Estimates","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2602189243","title":"Pacira 2025 preliminary revenue slightly misses expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2602189243","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602189243?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:12","pubTimestamp":1767906723,"startTime":"0","endTime":"0","summary":"Pacira 2025 preliminary revenue slightly misses expectationsOverviewNon-opioid pain therapy firm's preliminary 2025 revenue slightly missed analyst expectationsEXPAREL sales volume grew 7% in Q4, mark","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL1N3Y912H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4567","BK4588","BK4533","BK4007","PCRX","BK4149","LU0154245673.USD","LU0154245756.USD","LU0203347892.USD","LU0203345920.USD","CMI"],"gpt_icon":0},{"id":"2602183553","title":"Pacira Biosciences FY Revenue USD 726.4 Million VS. Ibes Estimate USD 737.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602183553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602183553?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:01","pubTimestamp":1767906060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nPLX9F157A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2602318806","title":"Press Release: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318806","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318806?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:01","pubTimestamp":1767906060,"startTime":"0","endTime":"0","summary":"-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years--. BRISBANE, Calif., Jan. 08, 2026  -- Pacira BioSciences, Inc. , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31, 2024. The company also repurchased 2.0 million shares of its common stock during the fourth quarter.\"We closed 2025 having achieved another year of solid execution and meaningful progress advancing our 5x30 strategic priorities, leaving us well-positioned for sustainable, long-term success,\" said Frank D. Lee, chief executive officer of Pacira BioSciences. \"Strong EXPAREL volume growth in the second half of the year underscores the value of our commercial investments and positions us for significant and sustai","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4007","BK4022","PCRX","R"],"gpt_icon":0},{"id":"2595725705","title":"It’s Earnings Warning Season. How to Profit From Others’ Misery","url":"https://stock-news.laohu8.com/highlight/detail?id=2595725705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595725705?lang=en_us&edition=fundamental","pubTime":"2026-01-01 23:00","pubTimestamp":1767279600,"startTime":"0","endTime":"0","summary":"January is an optimistic time of year for investors, but not necessarily for corporate America.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9c084b36ba0e1e4ad2a94bff2fcea0b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","CDNA","LU1974910355.USD","LU2362541513.USD","BK4139","BK4200","ANF","SLAB","LU2023250504.SGD","LU0058720904.USD","HALO","REGN","ILMN","LU0320765992.SGD","LU2237438978.USD","BK4202","BK4548","LU0823434740.USD","QDEL","IDCC","LU0823416689.USD","LU0889565916.HKD","LU1496350502.SGD","LU0289739699.SGD","LU0114720955.EUR","PCRX","IPAR","GMED","PTCT","LU2362540622.SGD","BK4535","LU0053666078.USD","LU0882574055.USD","BK4588","LU0823434583.USD","LU1917777945.USD","NVCR","ORC","EXAS","LU0109394709.USD","LU2468319806.SGD","LU2106854487.HKD","LU2362541273.HKD","BK4534","AEO","BK4121","LU2089984988.USD","STAA","LULU","BK4585","DXCM","FIVE","DHR","HOLX","TMUS","ALNY","BK4094","FOLD","LU0823411888.USD"],"gpt_icon":0},{"id":"2600703628","title":"Update: Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2600703628","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600703628?lang=en_us&edition=fundamental","pubTime":"2026-01-01 01:00","pubTimestamp":1767200441,"startTime":"0","endTime":"0","summary":"Pacira Biosciences  shareholder, DOMA Perpetual Capital Management, said Tuesday that it plans to nominate three independent director candidates at the company's annual meeting in 2026.DOMA said it owns about 6.83% of the company's shares and added that it is also calling for an immediate sale of the company, arguing that executive pay and overall spending are \"exorbitant and unmerited\" and that the board has not provided proper fiduciary oversight.\"Our Board is committed to enhancing long-term shareholder value and we take seriously feedback from our shareholders,\" Pacira Biosciences told MT Newswires, adding that it remains focused on carrying out its 5x30 strategy to drive growth.Price: 26.15, Change: +0.08, Percent Change: +0.31","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2595071510","title":"BRIEF-Doma Perpetual Capital Management Asserts Pacira Biosciences's Board To Pursue Sale Of Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2595071510","media":"Reuters","labels":["executive","corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595071510?lang=en_us&edition=fundamental","pubTime":"2025-12-30 23:45","pubTimestamp":1767109503,"startTime":"0","endTime":"0","summary":"BRIEF-Doma Perpetual Capital Management Asserts Pacira Biosciences's Board To Pursue Sale Of CompanyDec 30  - DOMA PERPETUAL CAPITAL MANAGEMENT:DOMA PERPETUAL CAPITAL MANAGEMENT ANNOUNCES INTENT TO NOMINATE THREE HIGHLY QUALIFIED, INDEPENDENT DIRECTOR CANDIDATES AT 2026 ANNUAL MEETING OF PACIRA BIOSCIENCES, INC.DOMA PERPETUAL CAPITAL MANAGEMENT: ASSERTS PACIRA BIOSCIENCES'S BOARD OF DIRECTORS SHOULD PURSUE AN IMMEDIATE SALE OF COMPANY","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nTUABDLFXZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2595715187","title":"Doma Perpetual Capital Management: Asserts Pacira Biosciences's Board of Directors Should Pursue an Immediate Sale of Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2595715187","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595715187?lang=en_us&edition=fundamental","pubTime":"2025-12-30 23:41","pubTimestamp":1767109306,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nTUABDLFXZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2595715947","title":"Press Release: DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2595715947","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595715947?lang=en_us&edition=fundamental","pubTime":"2025-12-30 23:41","pubTimestamp":1767109260,"startTime":"0","endTime":"0","summary":"Restates Position that Pacira's Board Should Conduct Formal Sales Process of the Business. Considers Current Executive Compensation and Spending Exorbitant and Unmerited. Questions Whether the Board Has Exercised Appropriate Fiduciary Oversight. MIAMI, Dec. 30, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC , which beneficially owns approximately 6.83% of the outstanding shares of Common Stock of Pacira BioSciences, Inc.  , today announced that it intends to nominate three highly-qualified, independent director candidates at the Company's 2026 annual meeting of stockholders. DOMA further asserts the Company's Board of Directors should pursue an immediate sale of the Company. DOMA considers the current level of Executive Compensation and General Spending to be exorbitant and unmerited and questions whether the Board has exercised appropriate fiduciary oversight.The participants in the proxy solicitation are anticipated to be DOMA, DOMA Perpetual LO Equity Master Fund LP, an ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4079","DOMA","BK4007"],"gpt_icon":0},{"id":"2594693872","title":"Pacira BioSciences (PCRX): How the New PROBE Consortium Partnership Shapes Its Current Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2594693872","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594693872?lang=en_us&edition=fundamental","pubTime":"2025-12-26 09:20","pubTimestamp":1766712016,"startTime":"0","endTime":"0","summary":"Pacira BioSciences (PCRX) just joined the PROBE Consortium, a European Innovative Health Initiative backed effort that uses AI and massive real world osteoarthritis datasets, and that move gives fresh context to the stock.\nSee our latest analysis for Pacira BioSciences.\nThe PROBE announcement lands at a time when sentiment around Pacira is quietly improving. A roughly 9 percent 1 month share price return has helped extend its strong year to date share price gains, even though the 3 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-how-the-new-probe-consortium-partner","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-how-the-new-probe-consortium-partner","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCRX","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":-0.1065},{"period":"1month","weight":-0.2676},{"period":"3month","weight":-0.1019},{"period":"6month","weight":-0.1155},{"period":"1year","weight":-0.1369},{"period":"ytd","weight":-0.2543}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.046386},{"month":2,"riseRate":0.642857,"avgChangeRate":0.021525},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.005065},{"month":4,"riseRate":0.6,"avgChangeRate":0.040098},{"month":5,"riseRate":0.533333,"avgChangeRate":0.021597},{"month":6,"riseRate":0.4,"avgChangeRate":0.013306},{"month":7,"riseRate":0.4,"avgChangeRate":-0.031855},{"month":8,"riseRate":0.533333,"avgChangeRate":0.016779},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.011519},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.02773},{"month":11,"riseRate":0.733333,"avgChangeRate":0.066003},{"month":12,"riseRate":0.6,"avgChangeRate":0.042036}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}